TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07499232: A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Di

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 530 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07499232 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07499232 Rescue Dossier →